Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.

Pediatric alopecia areata needs more research to understand its characteristics and related conditions.

People with alopecia areata are more likely to have anxiety and depression and a lower quality of life.

Gut bacteria may influence hair loss in alopecia areata.

Hair regrowth in Alopecia Areata patients leads to increased satisfaction and reduced stress.

Topical corticosteroids are recommended first for treating pediatric alopecia areata due to their safety and ease of use.

A new model uses specific blood markers to predict if children's hair loss will return.

A new treatment using nanoparticles can effectively prevent and reduce hair loss caused by chemotherapy.

Hair loss in Cronkhite-Canada syndrome may be caused by autoimmune factors, not just stress or malabsorption.

Caffeine shows promise for treating some types of hair loss, but more research is needed.

Hair loss was found in 37.4% of surveyed rural high-school students in Eskisehir, Turkey, affecting their quality of life, especially in general health and mental well-being.

The document concludes that hair loss is complex, affects many people, has limited treatments, and requires more research on its causes and psychological impact.

Dupilumab can improve both atopic dermatitis and alopecia universalis.

Deuruxolitinib effectively improves hair regrowth in alopecia areata but requires monitoring for side effects.

Upadacitinib is safe and effective for treating alopecia areata and atopic dermatitis in children.

Dupilumab and ustekinumab are promising treatments for alopecia areata, showing significant hair regrowth.

Altered hypothalamic activity may contribute to stress in alopecia areata patients.

Telemedicine is effective for managing alopecia areata follow-ups.

Children with atopic diseases have a higher risk of developing alopecia areata.

A mutation in the IL2RA gene increases the risk of alopecia areata.

AlopeciaDet accurately detects Alopecia Areata early using advanced image analysis.

Activated and non-activated PRP are equally safe and effective for treating alopecia areata.

Further research is needed to understand how the microbiome affects hair loss in Alopecia Areata.

Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.

Ritlecitinib may cause severe musculoskeletal pain in some alopecia universalis patients.

Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.

Alopecia areata greatly affects quality of life, with many experiencing mental health issues and lacking professional support.

Hair loss in alopecia areata can negatively affect sexual quality of life.

Baricitinib is effective and safe for treating alopecia areata in Korea.

The DPCP/HPβCD complex improves solubility and anti-inflammatory effects for alopecia areata treatment.